(NASDAQ: ARQT) Arcutis Biotherapeutics's forecast annual revenue growth rate of 28.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.7%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Arcutis Biotherapeutics's revenue in 2026 is $376,072,000.On average, 10 Wall Street analysts forecast ARQT's revenue for 2026 to be $62,719,960,276, with the lowest ARQT revenue forecast at $59,317,724,608, and the highest ARQT revenue forecast at $66,764,688,863. On average, 10 Wall Street analysts forecast ARQT's revenue for 2027 to be $81,390,705,268, with the lowest ARQT revenue forecast at $75,819,125,749, and the highest ARQT revenue forecast at $91,438,649,544.
In 2028, ARQT is forecast to generate $99,045,616,862 in revenue, with the lowest revenue forecast at $89,002,633,922 and the highest revenue forecast at $112,640,915,863.